The United States vaccines market size is projected to touch the figures of USD 30 Billion by 2027.
Highlighted with 19 tables and 93 figures, this 195-page report “United States Vaccines Market Size, Top 45 Vaccines Brand In-depth Analysis, Trends, Shares, Insights, and Forecasts to 2027” is based on comprehensive research of the United States vaccines market. The report offers the most up-to-date industry data on the actual market situation and future outlook for the United States vaccines market. The report provides historical market data for 2018 – 2020, and forecasts from 2021 until 2027. A comprehensive analysis has been done on market share with the percentage of all the 45 vaccines brand used in the United States.
The report contains a deep analysis of the United States vaccines market size in terms of value. The report provides a clear insight into current and future developments of the United States vaccines market. The report also explores the detailed analysis, insights of the top 45 vaccines market assessment in the United States from 2018 to 2020, and forecasts to 2027. A comprehensive analysis has been done on market share with a percentage of the leading 45 vaccines used in the United States. The report also details the latest information about the vaccine’s pricing analysis, insights, and trends, and the regulatory framework of the United States vaccines market.
The report also tracks and analyses competitive developments, including collaboration, partnership deals, distribution, exclusive and licensing agreements, new vaccine developments, and R&D activities in the market. The report also delivers an in-depth analysis of evolving market trends, drivers, and restraining forces that influence the growth of the market.
The report also analyses detailed profiles of innovative and leading players with information on business overview, companies’ vaccines portfolio, promising vaccines in the clinical development, and the latest developments
This Comprehensive U.S Vaccines Report Provides:
• The Market Size of the United States Vaccines Market with Six Years Forecast
• Detailed Insights of the Top 45 Vaccines Market Value Used in the U.S. with Six Years Forecast
• An Insightful Analysis of the Top 45 Vaccines Brand Market Share and Y-o-Y Growth Rate
• Delivers Comprehensive Insights on the Latest Pricing Analysis, Insights, and Trends
• Delivers an In-Depth Analysis of Evolving Market Trends, Drivers and Restraints of the United States Vaccines Market
• An Insightful Investigation has been done on Promising Vaccines in the Clinical Development
• Delivers Comprehensive Insights into the Regulatory Framework of the United States Vaccines Market
• Tracks Competitive Developments, Approaches, Recent Industry Developments, Partnership, Collaboration Deals, Distribution, Exclusive, and Licensing Agreement
• A Comprehensive List of the Leading Companies along with the Analysis of their Current Vaccines Portfolio, Promising Vaccines in the Clinical Development, and Recent Development
The Leading Companies for the U.S Vaccines Market are Listed Below:
• Pfizer
• Merck
• Grifols
• Sanofi Pasteur
• Seqirus (CSL Limited)
• AstraZeneca
• GlaxoSmithKline (GSK)
• Dynavax Technologies Corporation
The Following 45 Leading Vaccines Brand are Detailed with Market Value and Six-Years Forecast:
• Daptacel
• Quadracel
• Kinrix
• Pentacel
• Vaxelis
• IPOL
• Vaqta
• Havrix
• Twinrix
• Engerix B
• Recombivax HB
• PedvaxHIB
• ActHIB
• Hiberix
• MenQuadfi
• Tenivac
• Imovax
• Prevnar 13
• Gardasil 9
• Fluzone
• Flublok
• Fluad
• Varivax
• Menactra
• Proquad
• Pneumovax 23
• Fluarix/FluLaval
• M–M–R II
• Adacel
• Boostrix
• Bexsero
• Menveo
• Trumenba
• Shingrix
• Pentacel
• Recombivax HB
• Rotateq
• Rotarix
• Pediarix/Infanrix
• Heplisav–B
• TDVAX
• FluMist Quadrivalent
• Havrix/Twinrix/Engerix–B
• Flucelvax Quadrivalent
• Afluria Quadrivalent
The Report Helps Answer the Following Questions:
• What is the current scenario of the United States vaccines market?
• What is the total market size and forecast (until 2027) for the United States vaccines market?
• What are the leading vaccines? What are their revenue potentials to 2027?
• Which vaccine provides the highest market share?
• What is the regulatory framework in the United States vaccines market?
• What are the major growth drivers of the United States vaccines market?
• What are the major inhibitors of the United States vaccines market?
• What are the major deals and agreement happenings in the United States vaccines market?
• What are the United States vaccines pricing trends and analysis?
• What are the various vaccines available in the United States?
• Who are the top market players? What are their happenings, current developments, and scenarios?
• How is the market predicted to develop in the future?
'
1. Executive Summary
2. United States Vaccines Market Size and Forecast (2018 – 2027)
3. United States Vaccines Brand Market Share and Y–o–Y Growth (%), 2018 – 2027
4. Key Market Growth Drivers and Challenges in the U.S. Vaccines Market
4.1 Key Market Growth Drivers
4.2 Key Market Challenges
5. United States Top 45 Vaccines Market Value Analysis, Insights and Forecasts,2018 – 2027
5.1 Daptacel
5.2 Quadracel
5.3 Kinrix
5.4 Pentacel
5.5 Vaxelis
5.6 IPOL
5.7 Vaqta
5.8 Havrix
5.9 Twinrix
5.10 Engerix B
5.11 Recombivax HB
5.12 PedvaxHIB
5.13 ActHIB
5.14 Hiberix
5.15 MenQuadfi
5.16 Tenivac
5.17 Imovax
5.18 FluMist Quadrivalent
5.19 Prevnar 13
5.20 Gardasil 9
5.21 Fluzone Quadrivalent
5.22 Flublok
5.23 Flucelvax Quadrivalent
5.24 Afluria Quadrivalent
5.25 Fluad
5.26 Varivax
5.27 Menactra
5.28 Proquad
5.29 Pneumovax 23
5.30 Fluarix/FluLaval
5.31 Havrix/Twinrix/Engerix–B
5.32 M–M–R II
5.33 Adacel
5.34 Boostrix
5.35 Bexsero
5.36 Menveo
5.37 Trumenba
5.38 Shingrix
5.39 Pentacel
5.40 Recombivax HB
5.41 Rotateq
5.42 Rotarix
5.43 Pediarix/Infanrix
5.44 Heplisav–B
5.45 TDVAX
5.46 Other Vaccines
6. United States Vaccines Pricing Analysis, Insights and Trends
7. Regulatory Framework of the United States Vaccines Market
8. Major Deals and Agreement Happenings in the Vaccines Market
8.1 Collaboration Deals
8.2 Licensing Agreement
8.3 Exclusive Agreement
8.4 Distribution Agreement
8.5 Partnership Deals
9. Leading Companies in the United States Vaccines Market
9.1 Sanofi Pasteur
9.1.1 Business Overview
9.1.2 Vaccines Portfolio
9.1.3 Promising Vaccines in the Clinical Development
9.1.4 Recent Development
9.2 GlaxoSmithKline (GSK)
9.2.1 Business Overview
9.2.2 Vaccines Portfolio
9.2.3 Promising Vaccines in the Clinical Development
9.2.4 Recent Development
9.3 Merck
9.3.1 Business Overview
9.3.2 Vaccines Portfolio
9.3.3 Promising Vaccines in the Clinical Development
9.3.4 Recent Development
9.4 Pfizer
9.4.1 Business Overview
9.4.2 Vaccines Portfolio
9.4.3 Promising Vaccines in the Clinical Development
9.4.4 Recent Development
9.5 Seqirus (CSL Limited)
9.5.1 Business Overview
9.5.2 Vaccines Portfolio
9.5.3 Promising Vaccines in the Clinical Development
9.5.4 Recent Development
9.6 AstraZeneca
9.6.1 Business Overview
9.6.2 Vaccines Portfolio
9.6.3 Promising Vaccines in the Clinical Development
9.6.4 Recent Development
9.7 Dynavax Technologies Corporation
9.7.1 Business Overview
9.7.2 Vaccines Portfolio
9.7.3 Promising Vaccines in the Clinical Development
9.7.4 Recent Development
9.8 Grifols
9.8.1 Business Overview
9.8.2 Vaccines Portfolio
9.8.3 Recent Development
List of Tables
Table 3–1: United States Vaccines Brand Market Share & Y–o–Y Growth (Percent), 2018 – 2020
Table 3–2: United States Vaccines Brands Market Share & Y–o–Y Growth Forecast (Percent), 2021 – 2027
Table 6–1: United States Adult Vaccines Price, 2021 – 2022
Table 6–2: United States Adult Influenza Vaccines Price, 2021 – 2022
Table 6–3: United States Pediatric Vaccines Price, 2021 – 2022
Table 6–4: United States Pediatric Influenza Vaccines Price, 2021 – 2022
Table 7–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 8–1: Merger & Acquisitions in the Vaccines Market
Table 8–2: Collaboration Deal in the Vaccines Market
Table 8–3: Licensing Agreement in the Vaccines Market
Table 8–4: Exclusive Agreement in the Vaccines Market
Table 8–5: Distribution Agreement in the Vaccines Market
Table 8–6: Partnerships in the Vaccines Market
Table 9–1: Sanofi Promising Vaccines in the Clinical Development
Table 9–2: GSK Promising Vaccines in the Clinical Development
Table 9–3: Merck Promising Vaccines in the Clinical Development
Table 9–4: Pfizer Promising Vaccines in the Clinical Development
Table 9 5: Seqirus Promising Vaccines in the Clinical Development
Table 9–6: Dynavax Technologies Corporation Promising Vaccines in the Clinical Development
List of Figures
Figure 2–1: United States Vaccines Market Size (Million US$),2018 – 2020
Figure 2–2: United States Vaccines Market Size Forecast (Million US$),2021 – 2027
Figure 5–1: United States Daptacel Market Value (Million US$),2018 – 2020
Figure 5–2: United States Daptacel Market Value Forecast (Million US$),2021 – 2027
Figure 5–3: United States Quadracel Market Value (Million US$),2018 – 2020
Figure 5–4: United States Quadracel Market Value Forecast (Million US$),2021 – 2027
Figure 5–5: United States Kinrix Market Value (Million US$),2018 – 2020
Figure 5–6: United States Kinrix Market Value Forecast (Million US$),2021 – 2027
Figure 5–7: United States Pentacel Market Value (Million US$),2018 – 2020
Figure 5–8: United States Pentacel Market Value Forecast (Million US$),2021 – 2027
Figure 5–9: United States Vaxelis Market Value (Million US$),2018 – 2020
Figure 5–10: United States Vaxelis Market Value Forecast (Million US$),2021 – 2027
Figure 5–11: United States IPOL Market Value (Million US$),2018 – 2020
Figure 5–12: United States IPOL Market Value Forecast (Million US$),2021 – 2027
Figure 5–13: United States Vaqta Market Value (Million US$),2018 – 2020
Figure 5–14: United States Vaqta Market Value Forecast (Million US$),2021 – 2027
Figure 5–15: United States Havrix Market Value (Million US$),2018 – 2020
Figure 5–16: United States Havrix Market Value Forecast (Million US$),2021 – 2027
Figure 5–17: United States Twinrix Market Value (Million US$),2018 – 2020
Figure 5–18: United States Twinrix Market Value Forecast (Million US$),2021 – 2027
Figure 5–19: United States Engerix B Market Value (Million US$),2018 – 2020
Figure 5–20: United States Engerix B Market Value Forecast (Million US$),2021 – 2027
Figure 5–21: United States Recombivax HB Market Value (Million US$),2018 – 2020
Figure 5–22: United States Recombivax HB Market Value Forecast (Million US$),2021 – 2027
Figure 5–23: United States PedvaxHIB Market Value (Million US$),2018 – 2020
Figure 5–24: United States PedvaxHIB Market Value Forecast (Million US$),2021 – 2027
Figure 5–25: United States ActHIB Market Value (Million US$),2018 – 2020
Figure 5–26: United States ActHIB Market Value Forecast (Million US$),2021 – 2027
Figure 5–27: United States Hiberix Market Value (Million US$),2018 – 2020
Figure 5–28: United States Hiberix Market Value Forecast (Million US$),2021 – 2027
Figure 5–29: United States MenQuadfi Market Value and Forecast (Million US$),2020 – 2027
Figure 5–30: United States Tenivac Market Value (Million US$),2018 – 2020
Figure 5–31: United States Tenivac Market Value Forecast (Million US$),2021 – 2027
Figure 5–30: United States Imovax Market Value (Million US$),2018 – 2020
Figure 5–31: United States Imovax Market Value Forecast (Million US$),2021 – 2027
Figure 5–32: United States FluMist Quadrivalent Market Value (Million US$),2018 – 2020
Figure 5–33: United States FluMist Quadrivalent Market Value Forecast (Million US$),2021 – 2027
Figure 5–34: United States Prevnar 13 Market Value (Million US$),2018 – 2020
Figure 5–35: United States Prevnar 13 Market Value Forecast (Million US$),2021 – 2027
Figure 5–6: United States Gardasil 9 Market Value (Million US$),2018 – 2020
Figure 5–37: United States Gardasil 9 Market Value Forecast (Million US$),2021 – 2027
Figure 5–38: United States Fluzone Market Value (Million US$),2018 – 2020
Figure 5–39: United States Fluzone Market Value Forecast (Million US$),2021 – 2027
Figure 5–40: United States Flublok Market Value (Million US$), 2018 – 2020
Figure 5–41: United States Flublok Market Value Forecast (Million US$), 2021 – 2027
Figure 5–42: United States Flucelvax Quadrivalent Market Value (Million US$),2018 – 2020
Figure 5–43: United States Flucelvax Quadrivalent Market Value Forecast (Million US$),2021 – 2027
Figure 5–44: United States Afluria Quadrivalent Market Value (Million US$),2018 – 2020
Figure 5–45: United States Afluria Quadrivalent Market Value Forecast (Million US$),2021 – 2027
Figure 5–46: United States Fluad Market Value (Million US$),2018 – 2020
Figure 5–47: United States Fluad Market Value Forecast (Million US$),2021 – 2027
Figure 5–48: United States Varivax Market Value (Million US$),2018 – 2020
Figure 5–49: United States Varivax Market Value Forecast (Million US$),2021 – 2027
Figure 5–50: United States Menactra Market Value (Million US$),2018 – 2020
Figure 5–51: United States Menactra Market Value Forecast (Million US$),2021 – 2027
Figure 5–52: United States Proquad Market Value (Million US$),2018 – 2020
Figure 5–53: United States Proquad Market Value Forecast (Million US$),2021 – 2027
Figure 5–54: United States Pneumovax 23 Market Value (Million US$),2018 – 2020
Figure 5–55: United States Pneumovax 23 Market Value Forecast (Million US$),2021 – 2027
Figure 5–56: United States Fluarix/FluLaval Market Value (Million US$),2018 – 2020
Figure 5–57: United States Fluarix/FluLaval Market Value Forecast (Million US$),2021 – 2027
Figure 5–58: United States Havrix/Twinrix/Engerix–B Market Value (Million US$),2018 – 2020
Figure 5–59: United States Havrix/Twinrix/Engerix–B Market Value Forecast (Million US$),2021 – 2027
Figure 5–60: United States M–M–R ll Market Value (Million US$),2018 – 2020
Figure 5–61: United States M–M–R ll Market Value Forecast (Million US$),2021 – 2027
Figure 5–62: United States Adacel Market Value (Million US$),2018 – 2020
Figure 5–63: United States Adacel Market Value Forecast (Million US$),2021 – 2027
Figure 5–64: United States Boostrix Market Value (Million US$),2018 – 2020
Figure 5–65: United States Boostrix Market Value Forecast (Million US$),2021 – 2027
Figure 5–66: United States Bexsero Market Value (Million US$),2018 – 2020
Figure 5–67: United States Bexsero Market Value Forecast (Million US$),2021 – 2027
Figure 5–68: United States Menveo Market Value (Million US$),2018 – 2020
Figure 5–69: United States Menveo Market Value Forecast (Million US$),2021 – 2027
Figure 5–70: United States Trumenba Market Value (Million US$),2018 – 2020
Figure 5–71: United States Trumenba Market Value Forecast (Million US$),2021 – 2027
Figure 5–72: United States Shingrix Market Value (Million US$),2018 – 2020
Figure 5–73: United States Shingrix Market Value Forecast (Million US$),2021 – 2027
Figure 5–74: United States Pentacel Market Value (Million US$),2018 – 2020
Figure 5–75: United States Pentacel Market Value Forecast (Million US$),2021 – 2027
Figure 5–76: United States Recombivax HB Market Value (Million US$),2018 – 2020
Figure 5–77: United States Recombivax HB Market Value Forecast (Million US$),2021 – 2027
Figure 5–78: United States Rotateq Market Value (Million US$),2018 – 2020
Figure 5–79: United States Rotateq Market Value Forecast (Million US$),2021 – 2027
Figure 5–80: United States Rotarix Market Value (Million US$),2018 – 2020
Figure 5–81: United States Rotarix Market Value Forecast (Million US$),2021 – 2027
Figure 5–82: United States Pediarix/Infanrix Market Value (Million US$),2018 – 2020
Figure 5–83: United States Pediarix/Infanrix Market Value Forecast (Million US$),2021 – 2027
Figure 5–84: United States Heplisav–B Market Value & Forecast (Million US$),2018 – 2020
Figure 5–85: United States Heplisav–B Market Value & Forecast (Million US$),2021 – 2027
Figure 5–86: United States TDVAX Market Value (Million US$),2018 – 2020
Figure 5–87: United States TDVAX Market Value Forecast (Million US$),2021 – 2027
Figure 5–88: United States Other Vaccines Market Value (Million US$),2018 – 2020
Figure 5–89: United States Other Vaccines Market Value Forecast (Million US$),2021 – 2027
